Summary of AMP's Early January Trades

In the first week of January AMP started positions in Edge Therapeutics and Zealand Pharma and continued to build its positions in SC Pharmaceuticals and Protagonist Therapeutics.

AMP also further trimmed its Nektar Therapeutics positions which was up 400%+ at the time of the sales; netting AMP ~$27,000 in hypothetical gains.